Research

Cellular

INV-202 was well tolerated with no serious or severe treatment-emergent adverse events.

INV-202 appears to be a safe option for individuals with metabolic syndrome.

StrongSupportsmedium confidence
INV-202 was well tolerated with no serious or severe treatment-emergent adverse events.
Glenn Crater et al. · Diabetes Obesity and Metabolism · 2023

Why this rating

Based on study design from abstract.

Source

Effects of <scp>CB1R</scp> inverse agonist, <scp>INV</scp> ‐202, in patients with features of metabolic syndrome. A randomized, placebo‐controlled, double‐blind phase 1b study

Glenn Crater et al. · Diabetes Obesity and Metabolism · 2023

DOI 10.1111/dom.15353

rct · n=37Cited 40×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →